Jocelyn Dupuis

Professor of Medicine

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jocelyn Dupuis is a Professor of Medicine at the Montreal Heart Institute and Université de Montréal in Canada. Her research focuses on pulmonary hypertension, the effects of various therapeutic agents on cardiovascular diseases, and the impact of COVID-19 on pulmonary function. Recent articles include studies on the mechanisms of pulmonary hypertension and innovative therapeutic approaches in cardiopulmonary health.

Articles (11)

Year:

2025

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Eric Thorin

Professeur

Université de Montréal

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jocelyn Dupuis

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Binding of Hypoxia-Induced Mitogenic Factor/RELM-β to Bone Morphogenetic Protein Receptor 2 Complex Promotes Pulmonary Hypertension

MiR-1249 on Endothelial Extracellular Vesicles Mediates Cigarette Smoke–Induced Pulmonary Hypertension by Inhibiting HDAC10 (Histone Deacetylase 10)-NFκB (Nuclear Factor κB)-CaSR (Calcium-Sensing Receptor) Cascade

Fourteen-Day Evolution of COVID-19 Symptoms during the Third Wave in Nonvaccinated Subjects and Effects of Hesperidin Therapy: A Randomized, Double-Blinded, Placebo-Controlled Study

Right ventricular function and its coupling to pulmonary circulation predicts exercise tolerance in systolic heart failure

SPECT imaging of pulmonary vascular disease in bleomycin-induced lung fibrosis using a vascular endothelium tracer

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Dietary Geranylgeranyl Pyrophosphate Counteracts the Benefits of Statin Therapy in Experimental Pulmonary Hypertension.

Colchicine reduces lung injury in experimental acute respiratory distress syndrome

A Novel Molecular Pathway of Plaque Vulnerability Reveals a Cholesterol-Independent Effect of Statins and Supports Inflammation as a Therapeutic Target

Phenylalanine induces pulmonary hypertension through calcium-sensing receptor activation.

PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure

Collaborators (1)

Eric Thorin

Make your next move.